By Julia Ries, May 10, 2022

“This particular medication, Vivjoa, apparently has high efficacy with low recurrence risk—a boon to that subsection of the population so plagued with recurrent vulvovaginal yeast infections,” Kecia Gaither, MD, MPH, FACOG, a double board-certified ob-gyn and maternal fetal medicine specialist and director of perinatal services at NYC Health + Hospitals/Lincoln, told Health.

Click HERE for the full article.